Elaine M. Hylek, MD
Professor
Boston University School of Medicine
Dept of Medicine
General Internal Medicine

MD, University of Pittsburgh School of Medicine
MPH, Harvard School of Public Health
MS, University of Pittsburgh




Expertise includes: Arterial Thrombosis; Venous Thrombosis; Atrial Fibrillation; Safety and Effectiveness of Antithrombotic Therapy.

Active Staff Privileges
Boston Medical Center
Medicine



2011-2011 Other: Awarded Best Doctors in America 2007, 2009, 2011


Personnel agreement for research services of Elaine M. Hylek
01/01/2012 - 12/31/2013 (PI)
Department of Veterans Administration, Bedford


Personnel Agreement for Research Services of Elaine Hylek
01/01/2011 - 12/31/2013 (PI)
Department of Veterans Affairs


Phase II Study - Development and Implementation of Clinical Practice Guidelines in a Large Teaching Hospital for the Use of Fragmin as Bridging Therapy
07/01/2005 - 06/30/2007 (PI)
Pfizer, Inc.

Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) Registry
03/01/2005 - 02/28/2007 (PI)
Bristol-Myers Squibb

Differences in Baseline Patient Characteristics and Their Contribution to the Disparate Efficacy Conclusions of SPORTIF III and SPORTIF V
06/07/2005 - 12/06/2006 (PI)
AstraZeneca


Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement
02/16/2011 - 01/31/2017 (PI)
NIH-NHLBI
5R01 HL106029-05

Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation
09/30/2010 - 07/31/2015 (PI)
NIH-NINDS
5R01 NS070307-03

IPA Agreement - Guneet Jasuja
06/01/2013 - 08/31/2014 (PI)
VA

BRIDGE Trial
11/01/2009 - 10/31/2010 (PI)
Duke Clinical Research Inst NIH-NHLBI
U01 HL087229


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Guimarães PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Hijazi Z, Hylek EM, Gersh BJ, Garcia DA, Verheugt FWA, Hanna M, Flaker G, Vinereanu D, Granger CB. International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. J Thromb Thrombolysis. 2019 Jul; 48(1):27-34. PMID: 30972712.
     
  2. Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. J Am Heart Assoc. 2019 May 07; 8(9):e011205. PMID: 31023126.
     
  3. Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019 Apr; 47(3):345-352. PMID: 30790160.
     
  4. Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Chang P, Fonarow GC, Ezekowitz MD, Hylek E, Go AS, Kowey PR, Mahaffey KW, Gersh BJ, Peterson ED. Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). Am J Cardiol. 2019 May 15; 123(10):1628-1636. PMID: 30846214.
     
  5. Renda G, Patti G, Lang IM, Siller-Matula JM, Hylek EM, Ambrosio G, Haas S, De Caterina R. Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. Int J Cardiol. 2019 Jul 01; 286:198-207. PMID: 30777407.
     
  6. Hylek EM. Biomarkers for Prediction of Stroke and Bleeds in Atrial Fibrillation. Circulation. 2019 Feb 05; 139(6):772-774. PMID: 30715942.
     
  7. Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Chan P, Allen LA, Gersh BJ. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J. 2019 May; 211:77-89. PMID: 30901602.
     
  8. De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38. PMID: 30597497.
     
  9. Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 Feb; 208:123-131. PMID: 30579505.
     
  10. Hylek EM. Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle. Thromb Haemost. 2018 Dec; 118(12):2018-2019. PMID: 30453349.
     
Showing 10 of 249 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 249 publications over 26 distinct years, with a maximum of 30 publications in 2014

YearPublications
19921
19941
19951
19961
19981
19991
20003
20013
20021
20036
20043
20052
20066
200710
200815
200911
20108
201118
20129
201321
201430
201524
201625
201719
201822
20197
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Antithrombotic Therapy
Atrial Fibrillation
Intracranial Hemorrhage
Stroke
Thrombosis

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:


801 Massachusetts Ave Crosstown Center
Boston MA 02118
Google Map


Hylek's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department